Search

Biogen Inc

Fechado

SetorSaúde

218.55 -1.22

Visão Geral

Variação de preço das ações

24h

Atual

Mín

216.28

Máximo

221.5

Indicadores-chave

By Trading Economics

Rendimento

-639M

-320M

Vendas

258M

2.7B

P/E

Médio do Setor

38.469

57.366

EPS

3.6

Margem de lucro

-11.678

Funcionários

7,500

EBITDA

-475M

78M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+5.7% upside

Dividendos

By Acuity

Próximos Ganhos

29 de out. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.4B

32B

Abertura anterior

219.77

Fecho anterior

218.55

Sentimento de Notícias

By Acuity

23%

77%

59 / 340 Ranking em Healthcare

Biogen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de ago. de 2026, 20:08 UTC

News

Biogen Inc. has chosen Veeva Systems' Veeva Vault CRM to enhance its digital strategy, with shares rising during Wednesday's session amid positive sentiment.

25 de ago. de 2026, 23:26 UTC

Biogen Inc. shares are trading roughly flat in after-market hours. Crude oil prices have declined, easing some geopolitical tensions, impacting overall market sentiment.

24 de ago. de 2026, 20:13 UTC

Biogen Inc shares are trading lower in after-market hours. Broader market conditions may be influencing trading sentiment amid U.S.-Iran tensions and inflation concerns.

21 de ago. de 2026, 20:06 UTC

Biogen Inc is trading higher since Thursday's close, reflecting positive market trends. The stock remains above its 20-day moving average despite a recent pullback.

20 de ago. de 2026, 20:01 UTC

Correlated Moves

Shares lower today amid broader market declines and ETF drop.

19 de ago. de 2026, 23:06 UTC

Biogen Inc. shares declined in after-market trading, moving lower since Wednesday's close. The asset remains above its 20-day moving average.

17 de ago. de 2026, 19:46 UTC

Biogen Inc. shares are lower today amid routine trading, despite an unexpected rise in the New York manufacturing index supporting broader market conditions.

14 de ago. de 2026, 22:36 UTC

Biogen Inc's shares are higher in after-market trading, reflecting routine fluctuations. The stock remains above its 20-day moving average and near its monthly range high.

13 de ago. de 2026, 20:06 UTC

News

Wolfe Research upgraded Biogen to Outperform, raising its price target to $300, citing a promising late-stage pipeline and recent acquisition of Apellis Pharmaceuticals.

12 de ago. de 2026, 23:01 UTC

Biogen shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

11 de ago. de 2026, 23:46 UTC

Biogen Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement amid broader market focus on economic indicators.

10 de ago. de 2026, 19:36 UTC

Social Media

Biogen Inc has completed its $1 billion acquisition of RayThera. Shares are trading lower despite the strategic development and potential pipeline enhancement.

7 de ago. de 2026, 23:16 UTC

Social Media

Biogen Inc completed the acquisition of RayThera, valued at up to $1 billion, but shares are lower in after-market trading.

6 de ago. de 2026, 23:11 UTC

News

Biogen Inc. has completed its acquisition of RayThera Inc., enhancing its immunology portfolio. Shares are trading lower in after-market hours following a recent decline.

5 de ago. de 2026, 19:26 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Despite strong results, shares are trading lower amid broader market declines.

4 de ago. de 2026, 20:02 UTC

News

Mizuho raised its price target on Biogen Inc. to $241, contributing to the stock's upward movement during Tuesday's session.

3 de ago. de 2026, 23:06 UTC

Biogen Inc. shares are trading higher in after-market hours, supported by stronger-than-expected manufacturing data and positive broader market sentiment.

31 de jul. de 2026, 21:01 UTC

News

Biogen Inc reported second-quarter revenue of $2.74 billion, exceeding estimates. Shares are higher in after-market trading following the positive results and raised EPS guidance.

30 de jul. de 2026, 19:39 UTC

Biogen Inc shares are lower in Thursday's session, reaching a low of approximately -2.86% earlier. No specific news was identified to explain the decline.

29 de jul. de 2026, 22:02 UTC

Biogen Inc shares are higher in after-market hours, maintaining a steady upward trajectory since Wednesday's close and staying above the 20-day moving average.

28 de jul. de 2026, 22:01 UTC

Biogen Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains above its 20-day moving average.

27 de jul. de 2026, 18:56 UTC

Biogen Inc. shares are lower today amid routine trading fluctuations. Broader market declines are influenced by falling oil prices ahead of the Federal Reserve meeting.

24 de jul. de 2026, 18:26 UTC

Biogen Inc. shares are higher today, continuing an upward trend since Thursday. The stock's movement appears independent of recent oil price volatility.

22 de jul. de 2026, 22:01 UTC

Biogen Inc shares are trading higher in after-market hours, reflecting an increase since Wednesday's close amid broader market volatility and rising crude oil prices.

21 de jul. de 2026, 19:46 UTC

News

BIIB trading higher after Guggenheim raised price target to $280.

20 de jul. de 2026, 22:06 UTC

Biogen Inc. shares rose slightly in after-market hours, despite broader market pressure from a decline in the Conference Board's leading economic index.

17 de jul. de 2026, 20:02 UTC

Biogen Inc's shares are lower today, continuing a downward trend since Thursday. The broader market reflects a general decline amid notable sell-offs in technology stocks.

16 de jul. de 2026, 19:02 UTC

News

Biogen partners with Synapticure to launch a virtual ataxia care program. Shares are higher today, reflecting positive sentiment since Wednesday's close.

15 de jul. de 2026, 23:36 UTC

Biogen Inc. shares declined in after-market trading, reflecting ongoing weakness amid broader market caution related to geopolitical tensions involving the U.S. and Iran.

14 de jul. de 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

Comparação entre Pares

Variação de preço

Biogen Inc Previsão

Preço-alvo

By TipRanks

5.7% parte superior

Previsão para 12 meses

Média 234.13 USD  5.7%

Máximo 300 USD

Mínimo 157 USD

Com base em 27 analistas de Wall Street que oferecem metas de preço de 12 meses para Biogen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

27 ratings

17

Comprar

9

Manter

1

Vender

Sentimento

By Acuity

59 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat